Literature DB >> 16914696

Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease.

C W Zhu1, N Scarmeas, R Torgan, M Albert, J Brandt, D Blacker, M Sano, Y Stern.   

Abstract

OBJECTIVES: To estimate long-term trajectories of direct cost of caring for patients with Alzheimer disease (AD) and examine the effects of patients' characteristics on cost longitudinally.
METHODS: The sample is drawn from the Predictors Study, a large, multicenter cohort of patients with probable AD, prospectively followed up annually for up to 7 years in three university-based AD centers in the United States. Random effects models estimated the effects of patients' clinical and sociodemographic characteristics on direct cost of care. Direct cost included cost associated with medical and nonmedical care. Clinical characteristics included cognitive status (measured by Mini-Mental State Examination), functional capacity (measured by Blessed Dementia Rating Scale [BDRS]), psychotic symptoms, behavioral problems, depressive symptoms, extrapyramidal signs, and comorbidities. The model also controlled for patients' sex, age, and living arrangements.
RESULTS: Total direct cost increased from approximately 9,239 dollars per patient per year at baseline, when all patients were at the early stages of the disease, to 19,925 dollars by year 4. After controlling for other variables, a one-point increase in the BDRS score increased total direct cost by 7.7%. One more comorbid condition increased total direct cost by 14.3%. Total direct cost was 20.8% lower for patients living at home compared with those living in an institutional setting.
CONCLUSIONS: Total direct cost of caring for patients with Alzheimer disease increased substantially over time. Much of the cost increases were explained by patients' clinical and demographic variables. Comorbidities and functional capacity were associated with higher direct cost over time.

Entities:  

Mesh:

Year:  2006        PMID: 16914696     DOI: 10.1212/01.wnl.0000230160.13272.1b

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  49 in total

Review 1.  Alzheimer's disease: the strength of association of costs with different measures of disease severity.

Authors:  J Mauskopf; J Racketa; E Sherrill
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  Evidence for three loci modifying age-at-onset of Alzheimer's disease in early-onset PSEN2 families.

Authors:  Elizabeth E Marchani; Thomas D Bird; Ellen J Steinbart; Elisabeth Rosenthal; Chang-En Yu; Gerard D Schellenberg; Ellen M Wijsman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-07       Impact factor: 3.568

3.  Invited commentary: lipoproteins and dementia - is it the apolipoprotein A-I?

Authors:  Nikolaos Scarmeas
Journal:  Am J Epidemiol       Date:  2007-02-13       Impact factor: 4.897

Review 4.  A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.

Authors:  Mark Oremus; S Carolina Aguilar
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

5.  Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.

Authors:  Maurice W Dysken; Mary Sano; Sanjay Asthana; Julia E Vertrees; Muralidhar Pallaki; Maria Llorente; Susan Love; Gerard D Schellenberg; J Riley McCarten; Julie Malphurs; Susana Prieto; Peijun Chen; David J Loreck; George Trapp; Rajbir S Bakshi; Jacobo E Mintzer; Judith L Heidebrink; Ana Vidal-Cardona; Lillian M Arroyo; Angel R Cruz; Sally Zachariah; Neil W Kowall; Mohit P Chopra; Suzanne Craft; Stephen Thielke; Carolyn L Turvey; Catherine Woodman; Kimberly A Monnell; Kimberly Gordon; Julie Tomaska; Yoav Segal; Peter N Peduzzi; Peter D Guarino
Journal:  JAMA       Date:  2014-01-01       Impact factor: 56.272

Review 6.  Integrating care for older adults with cognitive impairment.

Authors:  Christopher M Callahan; Malaz Boustani; Greg A Sachs; Hugh C Hendrie
Journal:  Curr Alzheimer Res       Date:  2009-08       Impact factor: 3.498

7.  Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort.

Authors:  Anders Gustavsson; Linus Jönsson; Johan Parmler; Niels Andreasen; Carina Wattmo; Åsa K Wallin; Lennart Minthon
Journal:  Eur J Health Econ       Date:  2011-08-06

8.  Medicare expenditures among nursing home residents with advanced dementia.

Authors:  Keith S Goldfeld; David G Stevenson; Mary Beth Hamel; Susan L Mitchell
Journal:  Arch Intern Med       Date:  2011-01-10

9.  Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.

Authors:  Stephanie Behrens; Gail B Rattinger; Sarah Schwartz; Joshua Matyi; Chelsea Sanders; M Scott DeBerard; Constantine G Lyketsos; JoAnn T Tschanz
Journal:  Int Psychogeriatr       Date:  2018-03-21       Impact factor: 3.878

10.  The effects of patient function and dependence on costs of care in Alzheimer's disease.

Authors:  Carolyn W Zhu; Christopher Leibman; Trent McLaughlin; Nikolaos Scarmeas; Marilyn Albert; Jason Brandt; Deborah Blacker; Mary Sano; Yaakov Stern
Journal:  J Am Geriatr Soc       Date:  2008-07-24       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.